JP2023548443A5 - - Google Patents
Info
- Publication number
- JP2023548443A5 JP2023548443A5 JP2023551651A JP2023551651A JP2023548443A5 JP 2023548443 A5 JP2023548443 A5 JP 2023548443A5 JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023548443 A5 JP2023548443 A5 JP 2023548443A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- light chain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107942P | 2020-10-30 | 2020-10-30 | |
| US63/107,942 | 2020-10-30 | ||
| US202063123329P | 2020-12-09 | 2020-12-09 | |
| US202063123327P | 2020-12-09 | 2020-12-09 | |
| US63/123,327 | 2020-12-09 | ||
| US63/123,329 | 2020-12-09 | ||
| US202163141268P | 2021-01-25 | 2021-01-25 | |
| US63/141,268 | 2021-01-25 | ||
| US202163187719P | 2021-05-12 | 2021-05-12 | |
| US202163187699P | 2021-05-12 | 2021-05-12 | |
| US202163187690P | 2021-05-12 | 2021-05-12 | |
| US63/187,690 | 2021-05-12 | ||
| US63/187,719 | 2021-05-12 | ||
| US63/187,699 | 2021-05-12 | ||
| US202163189843P | 2021-05-18 | 2021-05-18 | |
| US63/189,843 | 2021-05-18 | ||
| PCT/US2021/057384 WO2022094299A2 (en) | 2020-10-30 | 2021-10-29 | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548443A JP2023548443A (ja) | 2023-11-16 |
| JP2023548443A5 true JP2023548443A5 (enExample) | 2024-11-07 |
Family
ID=81384468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551651A Pending JP2023548443A (ja) | 2020-10-30 | 2021-10-29 | Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230406937A1 (enExample) |
| EP (1) | EP4237013A4 (enExample) |
| JP (1) | JP2023548443A (enExample) |
| KR (1) | KR20230136913A (enExample) |
| AU (1) | AU2021369835A1 (enExample) |
| CA (1) | CA3196726A1 (enExample) |
| MX (1) | MX2023005081A (enExample) |
| WO (1) | WO2022094299A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP4149632A1 (en) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| CN116981682A (zh) * | 2020-12-08 | 2023-10-31 | 佳努克斯治疗公司 | 用于抗-cd3结合结构域的肽组合物和方法 |
| EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| AR125758A1 (es) | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| KR20250024874A (ko) * | 2022-04-04 | 2025-02-19 | 재눅스 테라퓨틱스 인크. | Psma 및 이펙터 세포 항원을 표적으로 하는 종양 활성화 항체와 관련된 조성물 및 방법 |
| AR129202A1 (es) * | 2022-05-04 | 2024-07-31 | Janux Therapeutics Inc | Anticuerpos activados por tumores que se dirigen a trop2 y usos de estos |
| EP4519326A4 (en) * | 2022-05-04 | 2026-05-06 | Janux Therapeutics Inc | TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| EP4615514A2 (en) * | 2022-11-10 | 2025-09-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| WO2024100451A2 (en) * | 2022-11-11 | 2024-05-16 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
| WO2024237744A1 (ko) * | 2023-05-18 | 2024-11-21 | 서울대학교산학협력단 | 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도 |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| WO2025090973A2 (en) * | 2023-10-27 | 2025-05-01 | Xencor, Inc. | Anti-trop2 x anti-pdl1 x anti-cd28 antibodies |
| TW202528349A (zh) * | 2023-11-03 | 2025-07-16 | 美商詹努克斯治療有限公司 | 用於靶向psma及cd28之抗體及其用途 |
| WO2025097024A1 (en) * | 2023-11-03 | 2025-05-08 | Janux Therapeutics, Inc. | Antibodies for targeting cd28 and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017024770A2 (pt) * | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| US20180179282A1 (en) * | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| AU2017337073A1 (en) * | 2016-09-30 | 2019-04-18 | Baylor College Of Medicine | Antibody based gene therapy with tissue-directed expression |
| WO2019005637A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| TWI917306B (zh) * | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
| CN112513077B (zh) * | 2018-07-09 | 2025-05-16 | 上海岸迈生物科技有限公司 | 高效表达的egfr和pd-l1双特异性结合蛋白 |
| US20200223925A1 (en) * | 2018-12-21 | 2020-07-16 | Hoffmann-La Roche Inc. | Tumor-targeted superagonistic cd28 antigen binding molecules |
| CR20210326A (es) * | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| EP3941941A1 (en) * | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
-
2021
- 2021-10-29 WO PCT/US2021/057384 patent/WO2022094299A2/en not_active Ceased
- 2021-10-29 CA CA3196726A patent/CA3196726A1/en active Pending
- 2021-10-29 AU AU2021369835A patent/AU2021369835A1/en active Pending
- 2021-10-29 EP EP21887650.6A patent/EP4237013A4/en active Pending
- 2021-10-29 US US18/249,886 patent/US20230406937A1/en active Pending
- 2021-10-29 KR KR1020237017803A patent/KR20230136913A/ko active Pending
- 2021-10-29 JP JP2023551651A patent/JP2023548443A/ja active Pending
- 2021-10-29 MX MX2023005081A patent/MX2023005081A/es unknown